MCRB vs. PALI
MCRB (Seres Therapeutics, Inc.) and PALI (Palisade Bio, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, MCRB returned -37.26%/yr vs -69.85%/yr for PALI. At a 0.17 correlation, their price movements are largely independent.
Performance
MCRB vs. PALI - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MCRB achieves a -58.94% return, which is significantly lower than PALI's -16.60% return. Over the past 10 years, MCRB has outperformed PALI with an annualized return of -37.26%, while PALI has yielded a comparatively lower -69.85% annualized return.
MCRB
- 1D
- -9.35%
- 1M
- 7.19%
- 6M
- -60.96%
- YTD
- -58.94%
- 1Y
- -51.39%
- 3Y*
- -59.76%
- 5Y*
- -57.21%
- 10Y*
- -37.26%
PALI
- 1D
- -0.51%
- 1M
- 14.62%
- 6M
- -1.51%
- YTD
- -16.60%
- 1Y
- 160.29%
- 3Y*
- -58.28%
- 5Y*
- -76.68%
- 10Y*
- -69.85%
MCRB vs. PALI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
MCRB Seres Therapeutics, Inc. | -58.94% | -10.47% | -40.64% | -75.00% | -32.77% | -66.00% | 610.14% | -23.67% | -55.42% | 2.42% |
PALI Palisade Bio, Inc. | -16.60% | 42.42% | -81.36% | -88.65% | -92.00% | -75.38% | -11.11% | -84.19% | -81.80% | -51.61% |
Correlation
The correlation between MCRB and PALI is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.16 |
Correlation (All Time) Calculated using the full available price history since Jun 26, 2015 | 0.17 |
Fundamentals
MCRB:
$59.17M
PALI:
$340.22M
MCRB:
-$5.17
PALI:
-$0.27
MCRB:
2.21
PALI:
3.23
MCRB:
$1.15M
PALI:
$0.00
MCRB:
$183.00K
PALI:
$0.00
MCRB:
-$47.68M
PALI:
-$26.58M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MCRB vs. PALI — Risk / Return Rank
MCRB
PALI
MCRB vs. PALI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Seres Therapeutics, Inc. (MCRB) and Palisade Bio, Inc. (PALI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MCRB | PALI | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.72 | ||
| Sortino ratioReturn per unit of downside risk | -2.76 | ||
| Omega ratioGain probability vs. loss probability | 0.96 | 1.28 | -0.31 |
| Calmar ratioReturn relative to maximum drawdown | -0.63 | 2.69 | -3.32 |
| Martin ratioReturn relative to average drawdown | -0.98 | 5.42 | -6.40 |
Loading charts...
Drawdowns
MCRB vs. PALI - Drawdown Comparison
The maximum MCRB drawdown since its inception was -99.45%, roughly equal to the maximum PALI drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for MCRB and PALI.
Loading charts...
Drawdown Indicators
| MCRB | PALI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.45% | -100.00% | +0.55% |
Max Drawdown (1Y)Largest decline over 1 year | -80.37% | -56.53% | -23.84% |
Max Drawdown (3Y)Largest decline over 3 years | -94.46% | -98.44% | +3.98% |
Max Drawdown (5Y)Largest decline over 5 years | -98.65% | -99.98% | +1.33% |
Max Drawdown (10Y)Largest decline over 10 years | -99.26% | -100.00% | +0.74% |
Current DrawdownCurrent decline from peak | -99.41% | -100.00% | +0.59% |
Average DrawdownAverage peak-to-trough decline | -81.53% | -76.39% | -5.14% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 51.79% | 28.01% | +23.78% |
Volatility
MCRB vs. PALI - Volatility Comparison
Seres Therapeutics, Inc. (MCRB) has a higher volatility of 27.56% compared to Palisade Bio, Inc. (PALI) at 25.61%. This indicates that MCRB's price experiences larger fluctuations and is considered to be riskier than PALI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MCRB | PALI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 27.56% | 25.61% | +1.95% |
Volatility (6M)Calculated over the trailing 6-month period | 70.63% | 62.43% | +8.20% |
Volatility (1Y)Calculated over the trailing 1-year period | 99.11% | 126.15% | -27.04% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 105.20% | 145.92% | -40.72% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 154.29% | 140.93% | +13.36% |
Dividends
MCRB vs. PALI - Dividend Comparison
Neither MCRB nor PALI has paid dividends to shareholders.
Financials
MCRB vs. PALI - Financials Comparison
This section allows you to compare key financial metrics between Seres Therapeutics, Inc. and Palisade Bio, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MCRB and PALI have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MCRB has higher volatility (27.56%) compared to PALI (25.61%). In terms of maximum drawdown, MCRB dropped -99.45% vs PALI's -100.00%.
PALI currently has the higher Sharpe Ratio (1.21 vs -0.51), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MCRB and PALI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer